氯贝丁酯对成年型糖尿病患者糖耐量的影响。
Effect of clofibrate on glucose tolerance in maturity onset diabetes.
作者信息
Barnett D, Craig J G, Robinson D S, Rogers M P
出版信息
Br J Clin Pharmacol. 1977 Aug;4(4):455-8. doi: 10.1111/j.1365-2125.1977.tb00761.x.
Abstract
1 Fourteen maturity onset diabetics showed improvement of glucose tolerance while on treatment with clofibrate. Fasting blood glucose levels were reduced by 20% after treatment for 14 and 28 days. 2 The effect was found to be independent of concurrent treatment with oral hypoglycaemic drugs. 3 Plasma insulin levels were also lower during clofibrate treatment. 4 Clofibrate may prove to be a useful adjunct to the treatment of maturity onset diabetes.
摘要
- 十四名成年起病的糖尿病患者在使用氯贝丁酯治疗期间，葡萄糖耐量有所改善。治疗14天和28天后，空腹血糖水平降低了20%。2. 发现该效果与同时使用口服降糖药无关。3. 在氯贝丁酯治疗期间，血浆胰岛素水平也较低。4. 氯贝丁酯可能被证明是成年起病糖尿病治疗的一种有用辅助药物。
相似文献
1
Effect of clofibrate on glucose tolerance in maturity onset diabetes.氯贝丁酯对成年型糖尿病患者糖耐量的影响。
Br J Clin Pharmacol. 1977 Aug;4(4):455-8. doi: 10.1111/j.1365-2125.1977.tb00761.x.
2
3
Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
Metabolism. 1977 Feb;26(2):129-39. doi: 10.1016/0026-0495(77)90048-8.
4
[The influence of clofibrate on glucose metabolism in diabetes mellitus without endogenous hypertriglyceridemia (author's transl)].
Arzneimittelforschung. 1982;32(4):413-6.
5
Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.
Diabetes Care. 1988 Jun;11(6):495-9. doi: 10.2337/diacare.11.6.495.
6
Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
Horm Metab Res. 1978 Jan;10(1):4-6. doi: 10.1055/s-0028-1093469.
7
[Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].安妥明对内源性高甘油三酯血症患者糖耐量及胰岛素分泌的影响（作者译）
MMW Munch Med Wochenschr. 1976 Mar 19;118(12):351-4.
8
Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.氯贝丁酯与口服降糖药治疗患者的血糖控制
Br J Clin Pharmacol. 1979 Jun;7(6):599-603. doi: 10.1111/j.1365-2125.1979.tb04649.x.
9
The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.氯贝丁酯对冠心病患者糖耐量、胰岛素分泌、甘油三酯及纤维蛋白原的影响。
Acta Med Scand. 1977;201(6):563-6. doi: 10.1111/j.0954-6820.1977.tb15748.x.
10
Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes.
Acta Diabetol Lat. 1976 May-Aug;13(3-4):107-10. doi: 10.1007/BF02581254.
引用本文的文献
1
Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?抗糖尿病药物：是癌症的治愈方法还是风险因素？
Pathol Oncol Res. 2018 Oct;24(4):745-755. doi: 10.1007/s12253-018-0402-z. Epub 2018 Mar 13.
2
Clofibrate inhibits the umami-savory taste of glutamate.氯贝丁酯会抑制谷氨酸的鲜味。
PLoS One. 2017 Mar 1;12(3):e0172534. doi: 10.1371/journal.pone.0172534. eCollection 2017.
3
Drug-induced hypoglycaemia: an update.药物诱导的低血糖症：更新。
Drug Saf. 2011 Jan 1;34(1):21-45. doi: 10.2165/11538290-000000000-00000.
4
Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.氯贝丁酯可增强非胰岛素依赖型糖尿病患者胰岛素受体的亲和力。
Br J Clin Pharmacol. 1984 Jan;17(1):89-91. doi: 10.1111/j.1365-2125.1984.tb05005.x.
5
Modification of intracellular glucose metabolism in human skin fibroblast preincubated with p-chlorophenoxyisobutyrate.对用对氯苯氧基异丁酸预先孵育的人皮肤成纤维细胞中细胞内葡萄糖代谢的修饰。
Br J Clin Pharmacol. 1987 Dec;24(6):763-7. doi: 10.1111/j.1365-2125.1987.tb03243.x.
6
Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).药物对非胰岛素依赖型糖尿病患者糖耐量的影响（第二部分）
Drugs. 1990 Aug;40(2):203-19. doi: 10.2165/00003495-199040020-00003.
7
Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.氯贝丁酯与口服降糖药治疗患者的血糖控制
Br J Clin Pharmacol. 1979 Jun;7(6):599-603. doi: 10.1111/j.1365-2125.1979.tb04649.x.
8
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.一项使用氯贝丁酯进行缺血性心脏病一级预防的合作试验。主要研究者委员会的报告。
Br Heart J. 1978 Oct;40(10):1069-118. doi: 10.1136/hrt.40.10.1069.
本文引用的文献
1
ATROMID IN THE TREATMENT OF POST-CLIMACTERIC DIABETES.
J Atheroscler Res. 1963 Sep-Dec;3:694-700. doi: 10.1016/s0368-1319(63)80054-x.
2
THE EFFECT OF ATROMID ON SERUM CHOLESTEROL AND GLUCOSE TOLERANCE IN DIABETES MELLITUS.
J Atheroscler Res. 1963 Sep-Dec;3:679-88. doi: 10.1016/s0368-1319(63)80052-6.
3
AN EXPERIMENTAL APPROACH TO THE PROBLEM OF DISORDERED LIPID METABOLISM.脂质代谢紊乱问题的实验性研究方法。
J Atheroscler Res. 1963 Sep-Dec;3:351-60. doi: 10.1016/s0368-1319(63)80017-4.
4
Immunoassay of insulin with insulin-antibody precipitate.用胰岛素 - 抗体沉淀物进行胰岛素免疫测定。
Biochem J. 1963 Jul;88(1):137-46. doi: 10.1042/bj0880137.
5
Hypolipidemic effect of chlorophenoxyisobutyrate in adult-onset diabetes mellitus.氯苯氧异丁酸酯在成年型糖尿病中的降血脂作用。
Clin Pharmacol Ther. 1966 Sep-Oct;7(5):631-8. doi: 10.1002/cpt196675631.
6
A colorimetric method for estimating serum triglycerides.一种估算血清甘油三酯的比色法。
Clin Chim Acta. 1968 Nov;22(3):393-7. doi: 10.1016/0009-8981(68)90041-7.
7
Long-term monitoring during clofibrate therapy.氯贝丁酯治疗期间的长期监测。
Clin Pharmacol Ther. 1970 Sep-Oct;11(5):689-97. doi: 10.1002/cpt1970115689.
8
Effect of CPIB ester on plasma free fatty acid levels in man.
Metabolism. 1966 Aug;15(8):673-5. doi: 10.1016/s0026-0495(66)80001-x.
9
Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus.
Clin Pharmacol Ther. 1965 Nov-Dec;6(6):716-30. doi: 10.1002/cpt196566716.
10
Long-term treatment of hyperlipidemic patients with clofibrate.
JAMA. 1971 Nov 15;218(7):1002-5.
Zotero 插件